February 23, 2021 -- Luminary Therapeutics has signed a license agreement with Bio-Techne for the use of its TcBuster chimeric antigen receptor (CAR) T technology for the manufacturing of gene-modified cell therapies.
TcBuster is Bio-Techne's proprietary nonviral transposon-based gene delivery system designed to advance cell therapy manufacturing. The use of TcBuster during the manufacturing of cell therapies allows for delivery of larger cargo, according to the firms.
Under the agreement, Bio-Techne has granted Luminary with a nonexclusive license for TcBuster. Luminary will use the technology in its LMY-920 program, a B-cell activating factor (BAFF) CAR T-cell therapy. Luminary plans to file an investigational new drug application with the U.S. Food and Drug Administration later this year.
Financial details of the agreement were not disclosed.